A multicenter, randomized trial evaluated the effectiveness of treatment for mild gestational diabetes. Women with mild gestational diabetes (defined by abnormal glucose tolerance test results but fasting glucose <95 mg/dL) were randomly assigned to either usual prenatal care or treatment involving dietary intervention, blood glucose monitoring, and insulin if needed. The primary outcome was a composite of stillbirth, neonatal death, and neonatal complications like hypoglycemia, hyperbilirubinemia, hyperinsulinemia, and birth trauma. No significant difference was found between groups in the composite outcome (32.4% vs. 37.0%). However, treatment significantly reduced several secondary outcomes, including mean birth weight (3302 vs. 3408 g), neonatal fat mass, the frequency of large-for-gestational-age infants, birth weight >4000 g, shoulder dystocia, and cesarean delivery. Treatment also reduced the rates of preeclampsia and gestational hypertension. The study found that while treatment did not significantly reduce the composite perinatal outcome, it did lower the risks of fetal overgrowth, shoulder dystocia, cesarean delivery, and hypertensive disorders. Gestational diabetes is a recognized marker for increased future diabetes risk, but its clinical significance for adverse pregnancy outcomes remains uncertain. The HAPO study showed a strong association between maternal glucose levels and perinatal complications, even at levels below typical diagnostic thresholds for gestational diabetes. Professional organizations recommend screening for gestational diabetes, but evidence for the benefit of mild carbohydrate intolerance treatment is limited. The ACHOIS trial found that treatment reduced serious perinatal complications and improved health-related quality of life. However, the U.S. Preventive Services Task Force concluded that current evidence is insufficient to assess the balance of benefits and harms of screening and treatment. The study used a 100-g oral glucose-tolerance test for diagnosis and included a control group with normal glucose tolerance results to mask their status. Women in the treatment group had lower rates of cesarean delivery, shoulder dystocia, and preeclampsia. The study also found that treatment led to lower body mass index and weight gain, and that glycemic targets were achieved in the treatment group. The results suggest that while treatment of mild gestational diabetes does not significantly reduce the composite perinatal outcome, it does reduce the risk of several adverse outcomes. The findings support the identification and treatment of mild carbohydrate intolerance during pregnancy, but further research is needed to determine long-term effects on offspring health.A multicenter, randomized trial evaluated the effectiveness of treatment for mild gestational diabetes. Women with mild gestational diabetes (defined by abnormal glucose tolerance test results but fasting glucose <95 mg/dL) were randomly assigned to either usual prenatal care or treatment involving dietary intervention, blood glucose monitoring, and insulin if needed. The primary outcome was a composite of stillbirth, neonatal death, and neonatal complications like hypoglycemia, hyperbilirubinemia, hyperinsulinemia, and birth trauma. No significant difference was found between groups in the composite outcome (32.4% vs. 37.0%). However, treatment significantly reduced several secondary outcomes, including mean birth weight (3302 vs. 3408 g), neonatal fat mass, the frequency of large-for-gestational-age infants, birth weight >4000 g, shoulder dystocia, and cesarean delivery. Treatment also reduced the rates of preeclampsia and gestational hypertension. The study found that while treatment did not significantly reduce the composite perinatal outcome, it did lower the risks of fetal overgrowth, shoulder dystocia, cesarean delivery, and hypertensive disorders. Gestational diabetes is a recognized marker for increased future diabetes risk, but its clinical significance for adverse pregnancy outcomes remains uncertain. The HAPO study showed a strong association between maternal glucose levels and perinatal complications, even at levels below typical diagnostic thresholds for gestational diabetes. Professional organizations recommend screening for gestational diabetes, but evidence for the benefit of mild carbohydrate intolerance treatment is limited. The ACHOIS trial found that treatment reduced serious perinatal complications and improved health-related quality of life. However, the U.S. Preventive Services Task Force concluded that current evidence is insufficient to assess the balance of benefits and harms of screening and treatment. The study used a 100-g oral glucose-tolerance test for diagnosis and included a control group with normal glucose tolerance results to mask their status. Women in the treatment group had lower rates of cesarean delivery, shoulder dystocia, and preeclampsia. The study also found that treatment led to lower body mass index and weight gain, and that glycemic targets were achieved in the treatment group. The results suggest that while treatment of mild gestational diabetes does not significantly reduce the composite perinatal outcome, it does reduce the risk of several adverse outcomes. The findings support the identification and treatment of mild carbohydrate intolerance during pregnancy, but further research is needed to determine long-term effects on offspring health.